Compare Incyte Corporation (INCY) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Solaredge Technologies Inc — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Solaredge Technologies Inc trades at $50.4 (market cap $2.96B). The key difference: Incyte Corporation is far larger — about 7.8× Solaredge Technologies Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SEDG | |
|---|---|---|
Market Cap | $23.11B | $2.96B |
Sector | Health | Technology |
52-Week High | $118.52 | $78.51 |
52-Week Low | $67.38 | $24.42 |
Enterprise Value | $19.13B | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SolarEdge Technologies (SEDG) trades at $48.65, down 9.01% in the last session, reflecting ongoing volatility. The stock shows a bearish technical signal with mixed earnings history—beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue declined to $1.18 billion in 2025, with a net loss of $405.45 million, though operating cash flow improved to $104.26 million. Analyst consensus is divided, with a hold-heavy rating and a $35.65 price target below the current price.
The outlook remains challenging due to persistent losses and competitive pressures, but potential catalysts include upcoming Q2 2026 earnings and demand for solar solutions. Key risks include high debt, margin pressures, and market sentiment shifts. Investors should weigh cost-cutting progress against sector headwinds for recovery potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
